indomethacin
Trade name: indocin
Approved
Jun 10, 1965
Indometacin (INN and BAN) or indomethacin (AAN, USAN, and former BAN) is a nonsteroidal anti-inflammatory drug (NSAID) commonly used as a prescription medication to reduce fever, pain, stiffness, and swelling from inflammation. Indomethacin has analgesic, anti-inflammatory, and antipyretic properties. The mechanism of action of Indometacin, like that of other NSAIDs, is not completely understood but involves inhibition of cyclooxygenase (COX-1 and COX-2). Indomethacin is a potent inhibitor of prostaglandin synthesis in vitro. Indomethacin concentrations reached during therapy have produced in vivo effects. Prostaglandins sensitize afferent nerves and potentiate the action of bradykinin in inducing pain in animal models. Prostaglandins are mediators of inflammation. Because indomethacin is an inhibitor of prostaglandin synthesis, its mode of action may be due to a decrease of prostaglandins in peripheral tissues. Indometacin is indicated for: Moderate to severe rheumatoid arthritis including acute flares of chronic disease, Moderate to severe ankylosing spondylitis, Moderate to severe osteoarthritis, Acute painful shoulder (bursitis and/or tendinitis), Acute gouty arthritis. In general, adverse effects seen with indomethacin are similar to all other NSAIDs. For instance, indometacin inhibits both cyclooxygenase-1 and cyclooxygenase-2, it inhibits the production of prostaglandins in the stomach and intestines, which maintain the mucous lining of the gastrointestinal tract. Indometacin, therefore, like other non-selective COX inhibitors can cause peptic ulcers. These ulcers can result in serious bleeding and/or perforation requiring hospitalization of the patient. To reduce the possibility of peptic ulcers, indomethacin should be prescribed at the lowest dosage needed to achieve a therapeutic effect, usually between 50–200 mg/day. It should always be taken with food. Nearly all patients benefit from an ulcer protective drug (e.g. highly dosed antacids, ranitidine 150 mg at bedtime, or omeprazole 20 mg at bedtime). Other common gastrointestinal complaints, including dyspepsia, heartburn and mild diarrhea are less serious and rarely require discontinuation of indomethacin. — NCATS
Clinical trial activity
137 trials · 170 clinical orgs · 45 marketing orgs
Earliest trial started Sep 1, 1978 (NCT00000494)
Timeline
1960s
- Jun 10, 1965
Merck — Earliest FDA Approval
- Jun 10, 1965
Zyla Life Sciences — NDA Secondary Org
- Jun 10, 1965
Merck — NDA Organization
1970s
- Jan 1, 1978
Earliest Phase 3 Sponsor(trial)
1980s
- Apr 20, 1984
Rising Pharmaceuticals — Marketing Organization
- Apr 20, 1984
Mylan — NDA Secondary Org
- Apr 20, 1984
Rising Pharmaceuticals — NDA Secondary Org
- May 4, 1984
Teva — NDA Secondary Org
- May 18, 1984
Heritage Pharma — NDA Secondary Org
- Jun 21, 1984
Chartwell Pharmaceuticals — NDA Secondary Org
- Jan 30, 1985
Recordati — NDA Secondary Org
- Oct 10, 1985
Zyla Life Sciences — Marketing Organization
- Oct 18, 1985
Duramed Research — Marketing Organization
- Nov 7, 1985
Teva — Marketing Organization
- Feb 12, 1986
Heritage Pharma — Marketing Organization
- Oct 3, 1986
Mutual Pharmaceutical — Marketing Organization
- Oct 10, 1986
Superpharm — Marketing Organization
- Mar 18, 1987
Pliva — Marketing Organization
- Mar 18, 1987
Ani Pharmaceuticals — Marketing Organization
- Mar 18, 1987
Hikma — Marketing Organization
- Apr 29, 1987
Sandoz — Marketing Organization
- May 18, 1987
Watson Pharmaceuticals — Marketing Organization
- Mar 15, 1989
Inwood Laboratories — Marketing Organization
1990s
- Aug 31, 1992
G & W Laboratories Inc. — Marketing Organization
- Aug 31, 1992
ACP Nimble — Marketing Organization
- Aug 31, 1992
Cosette — Marketing Organization
- Jan 1, 1993
Earliest Phase 2 Sponsor(trial)
- Jan 1, 1997
Earliest Phase 1 Sponsor(trial)
- May 28, 1998
Novartis — Marketing Organization
2000s
- Feb 6, 2002
Able Laboratories — Marketing Organization
- Jul 16, 2008
West-Ward Pharmaceutical — Marketing Organization
- Mar 6, 2009
Avanthi Pharma — Marketing Organization
2010s
- Mar 17, 2010
Fresenius — NDA Secondary Org
- Nov 15, 2010
Cadila Healthcare — Marketing Organization
- Nov 30, 2010
Chartwell Pharmaceuticals — Marketing Organization
- Dec 1, 2010
Amneal Pharmaceuticals — Marketing Organization
- Dec 22, 2010
Glenmark Pharmaceuticals — Marketing Organization
- Apr 12, 2011
Hetero Labs Ltd — Marketing Organization
- Mar 28, 2013
Sun Pharmaceuticals — Marketing Organization
- Dec 9, 2013
Actavis — Marketing Organization
- Feb 24, 2014
Genus Oncology, LLC — Marketing Organization
- Feb 24, 2014
Genus Oncology, LLC — NDA Secondary Org
- Oct 5, 2015
Jubilant Innovation Ltd. — Marketing Organization
- Apr 19, 2016
Hospira — Marketing Organization
- Apr 19, 2016
Pfizer — Marketing Organization
- Dec 27, 2016
Aurobindo Pharma — Marketing Organization
- May 8, 2017
Novast Labs — Marketing Organization
- Jul 19, 2017
Navinta — Marketing Organization
- Sep 25, 2017
Zydus Discovery DMCC — Marketing Organization
2020s
- Jan 12, 2024
Novitium Pharma — Marketing Organization
- Jul 3, 2025
Annora Pharma — Marketing Organization
Indications
Approved for
Studied for
- Acute Pain · Phase 3
- Adenocarcinoma · Phase 1/Phase 2
- Alzheimer Disease · Phase 3
- Ankle Injuries · Phase 4
- Anti-Bacterial Agents · Phase 4
- Arthralgia · Phase 2
- Arthritis, Gouty · Phase 3
- Asthma · Phase 2
- Axial Spondyloarthritis · Phase 4
- Azithromycin · Phase 4
- Brain Injuries · Phase 1/Phase 2
- Breast Neoplasms · Phase 2
- Breast Neoplasms, Male · Phase 1
- Carcinoma, Squamous Cell · Phase 2
- Cardiovascular Diseases · Phase 3
- Cataract · Phase 4
- Cefazolin · Phase 4
- Cerebral Intraventricular Hemorrhage · Phase 3
- Cerebrovascular Circulation · Early Phase 1
- Colitis, Ulcerative · Phase 1
- Colonic Neoplasms · Phase 1/Phase 2
- Colorectal Neoplasms · Phase 4
- Cough · Phase 3
- COVID-19 · Phase 3
- Drug Interactions · Phase 1
- Ductus Arteriosus, Patent · Phase 4
- Electroencephalography · Phase 2
- Enuresis · Phase 4
- Esophageal Neoplasms · Phase 1
- Family Planning Services · Phase 4
- Fatty Acids · Phase 2
- Fertilization in Vitro · Phase 3
- Gastrointestinal Diseases · Phase 4
- Gout · Phase 4
- Healthy Volunteers · Phase 4
- Heart Defects, Congenital · Phase 3
- Heart Diseases · Phase 3
- Hemorrhage · Phase 4
- Histiocytosis, Langerhans-Cell · Phase 2/Phase 3
- Hypertension · Phase 1/Phase 2
- Hypotension, Orthostatic · Phase 1
- Infant, Premature · Phase 3
- Infant, Premature, Diseases · Phase 3
- Infant, Very Low Birth Weight · Phase 3
- Inflammation · Phase 4
- Intestinal Neoplasms · Phase 1
- Kidney Diseases · Phase 1/Phase 2
- Labor, Obstetric · Phase 2
- Leukomalacia, Periventricular · Phase 1/Phase 2
- Live Birth · Phase 4
- Macular Edema · Phase 4
- Melanoma · Phase 2
- Metabolic Syndrome · Early Phase 1
- Mortality · Phase 3
- Multiple Organ Failure · Phase 3
- Neonatology · Phase 3
- Neuromuscular Junction · Phase 4
- Obstetric Labor Complications · Phase 4
- Obstetric Labor, Premature · Phase 4
- Orthostatic Intolerance · Phase 1/Phase 2
- Osteoarthritis · Phase 4
- Ovarian Neoplasms · Phase 1
- Ovulation · Phase 4
- Pain · Phase 3
- Pancreatectomy · Phase 2
- Pancreatitis · Phase 4
- Pancreatitis, Chronic · Phase 2
- Physiological Effects of Drugs · Phase 4
- Postoperative Pain · Phase 4
- Pregnancy Complications · Phase 4
- Premature Birth · Phase 4
- Prostatic Neoplasms · Phase 2
- Pure Autonomic Failure · Phase 1
- Regional Blood Flow · Phase 2
- Renal Colic · Phase 3
- Sleep Apnea, Obstructive · Phase 1/Phase 2
- Squamous Cell Carcinoma of Head and Neck · Phase 2
- Stroke · Phase 1/Phase 2
- Tachycardia · Phase 1/Phase 2
- Triple Negative Breast Neoplasms · Phase 1
- Uterine Cervical Incompetence · Phase 4
- Uterine Cervical Neoplasms · Phase 2
- Vulvar Neoplasms · Phase 2
Mechanism of action
- CyclooxygenaseINHIBITOR
Cyclooxygenase inhibitor
Approval history
- approvedPriority reviewJun 10, 1965
Chemistry & pharmacology
SMILES
COc1ccc2c(c1)c(CC(=O)[O-])c(C)n2C(=O)c1ccc(Cl)cc1.O.O.O.[Na+]- Mol. weight
- 433.82 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
- Delivery
- Parenteral
- Availability
- Prescription Only
Oral
No
Parenteral
Yes
Topical
No
Sources
- ChEMBLCHEMBL3989410 ↗
- WikipediaIndometacin ↗
- NCATSXXE1CET956 ↗
- ChEMBLCHEMBL6 ↗
- ChEMBLCHEMBL1200864 ↗
- ChEMBLCHEMBL2107410 ↗
- ChEMBLCHEMBL488914 ↗
- ChEMBLCHEMBL2146132 ↗
Also known as
- {1-[(4-chlorophenyl)carbonyl]-5-methoxy-2-methyl-1h-indol-3-yl}acetic acid
- {1-[(4-chlorophenyl)carbonyl]-5-methoxy-2-methyl-1h-indol-3-yl}acetic acid
- 1-(p-chlorobenzoyl)-5-methoxy-2-methylindole-3-acetic acid
- 1-(p-chlorobenzoyl)-5-methoxy-2-methylindole-3-acetic acid
- aconip
- aconip
- artracin
- artracin
- artracin sr
- berlind 75 ret
- flexin-25 continus
- flexin-50 continus
- flexin-75 continus
- glucametacin
- glucametacin
- glucametacin
- glucametacin
- glucametacin
- glucametacine
- glucamethacin
- imbrilon
- imbrilon
- indocid-r
- indocid ret
- indocin
- indocin
- indocin
- indocin
- indocin
- indocin sr
- indocin sr
- indoderm
- indoflex
- indolar
- indolar
- indolar sr
- indolar sr
- indo-lemmon
- indo-lemmon
- indomax-25
- indomax-75 sr
- indometacin
- indometacin
- indometacin
- indometacin
- indometacina
- indometacina
- indometacine
- indometacine
- indometacine
- indometacin farnesil
- indometacin farnesil
- indometacin farnesil
- indometacinum
- indometacinum
- indomethacin
- indomethacin
- indomethacin
- indomethacin
- indomethacin
- indomethacin
- indomethacin
- indomethacin
- indomethacin
- indomethacin
- indomethacine
- indomethacin farnesil
- indomethacin glucosamide
- indomethacin hcl
- indomethacin hydrochloride
- indomethacin hydrochloride
- indomethacin hydrochloride
- indomethacin hydrochloride
- indomethacin hydrochloride
- indomethacin hydrochloride
- indomethacin sodium
- indomethacin sodium
- indomethacin sodium
- indomethacin sodium
- indomod
- indomod
- indo-paed
- indoptol
- indoptol
- indotard mr 75
- ledmecin
- maximet sr
- mobilan
- mobilan
- mobilan
- pardelprin mr
- rheumacin la
- rheumacin la
- rimacid
- slo-indo
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07218653 | Early Phase 1 (Phase 1) | Jul 31, 2026 | National Institutes of Health (NIH), University of Wisconsin |
| NCT07202559 | N/A | Dec 1, 2025 | Baotou Medical University, Central South University, Changhai Hospital, Chinese Academy of Medical Sciences, First People's Hospital of Hangzhou, Jiao Tong University, Ningxia Medical University, Shandong University, Yunnan University of Traditional Chinese Medicine |
| NCT07088757 | Phase 4 | Sep 15, 2025 | Changhai Hospital, Dongyang People's Hospital, Jiao Tong University, Jinhua Central Hospital, Nanchang University, Ningbo University, People's Hospital of Quzhou, Shaoxing People's Hospital, Taizhou Enze Medical Center Group, Zhejiang University, Zhuji People's Hospital of Zhejiang Province |
| NCT07071441 | N/A | Jun 1, 2025 | Air Force Military Medical University, China |
| NCT06572917 | Phase 3 | Jun 1, 2025 | University of British Columbia |
| NCT06433453 | Phase 4 | Apr 22, 2024 | University of Saskatchewan |
| NCT05999708 | Phase 1 | Oct 31, 2023 | GlaxoSmithKline |
| NCT05947461 | N/A | Jun 1, 2023 | Air Force Military Medical University, China |
| NCT05857514 | N/A | May 10, 2023 | Moti Lal Nehru Medical College, Sheffield Hallam University |
| NCT05722548 | Phase 2 | Feb 1, 2023 | Jiao Tong University |
| NCT05252754 | Phase 3 | Jan 1, 2023 | Johns Hopkins University |
| NCT05538247 | Early Phase 1 (Phase 1) | Dec 15, 2022 | Mayo Clinic |
| NCT05637281 | N/A | Dec 11, 2022 | Zhejiang University |
| NCT05664074 | Phase 4 | Nov 7, 2022 | University of Cincinnati |
| NCT06031363 | N/A | Nov 1, 2022 | Soochow University |
| NCT07173179 | Phase 4 | Jul 1, 2022 | Duke University |
| NCT05381428 | Phase 3 | May 13, 2022 | University of Modena and Reggio Emilia, University of Parma |
| NCT05007522 | Phase 3 | Dec 1, 2021 | Duke University, National University of Singapore, Sen-Jam Pharmaceutical |
| NCT05132829 | Phase 4 | Nov 30, 2021 | Thomas Jefferson University |
| NCT04821323 | Early Phase 1 (Phase 1) | Mar 10, 2021 | Janssen Pharmaceutica NV |
Organizations
Research & Development (170)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Jiao Tong University | Academic/Hospital | 5 | 3 | 3 | 2016 |
| Changhai Hospital | Academic/Hospital | 4 | 3 | 3 | 2016 |
| Hebrew University | Academic/Hospital | 4 | 4 | 2 | 2002 |
| Iroko | For profit | 4 | 4 | 2 | 2009 |
| National Cancer Institute (NCI) | Government | 4 | 1 | 1 | 1997 |
| People's Liberation Army of China | Government | 4 | 3 | 2 | 2013 |
| University of Michigan | Academic/Hospital | 4 | 1 | 3 | 2005 |
| University of Wisconsin | Academic/Hospital | 4 | 3 | 3 | 1993 |
| Case Western Reserve University | Academic/Hospital | 3 | 1 | 3 | 1993 |
| IRX Therapeutics | For profit | 3 | 2 | 2 | 2005 |
| Mayo Clinic | Academic/Hospital | 3 | 3 | 2 | 2015 |
| National Institutes of Health (NIH) | Government | 3 | 0 | 2 | 1997 |
| Radboud University | Academic/Hospital | 3 | 2 | 3 | 2000 |
| University of Calgary | Academic/Hospital | 3 | 3 | 2 | 1997 |
| Zhejiang University | Academic/Hospital | 3 | 1 | 3 | 2019 |
| Aarhus University | Academic/Hospital | 2 | 1 | 2 | 2003 |
| Air Force Military Medical University, China | Academic/Hospital | 2 | 2 | 1 | 2023 |
| Boehringer Ingelheim | For profit | 2 | 2 | 2 | 2000 |
| Brock University | Academic/Hospital | 2 | 2 | 1 | 2013 |
| Cairo University | Academic/Hospital | 2 | 2 | 1 | 2014 |
Marketing (69)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| ACP Nimble | For profit | MKTG | Aug 31, 1992 |
| Able Laboratories | For profit | MKTG | Feb 6, 2002 |
| Actavis | For profit | MKTG | Dec 9, 2013 |
| Amneal Pharmaceuticals | For profit | MKTG | Dec 1, 2010 |
| Amneal Pharmaceuticals | For profit | SYN | Feb 24, 2025 |
| Ani Pharmaceuticals | For profit | SYN | Mar 18, 1987 |
| Ani Pharmaceuticals | For profit | MKTG | Mar 18, 1987 |
| Annora Pharma | For profit | MKTG | Jul 3, 2025 |
| Aurobindo Pharma | For profit | MKTG | Dec 27, 2016 |
| Aurobindo Pharma | For profit | SYN | Dec 27, 2016 |
| Avanthi Pharma | For profit | MKTG | Mar 6, 2009 |
| Cadila Healthcare | For profit | MKTG | Nov 15, 2010 |
| Chartwell Pharmaceuticals | For profit | NDA2 | Jun 21, 1984 |
| Chartwell Pharmaceuticals | For profit | MKTG | Nov 30, 2010 |
| Cosette | For profit | MKTG | Aug 31, 1992 |
| Cycle Pharmaceuticals Ltd. | For profit | MKTG | — |
| Dow Chemical | For profit | MKTG | — |
| Duramed Research | For profit | MKTG | Oct 18, 1985 |
| Fresenius | For profit | NDA2 | Mar 17, 2010 |
| G & W Laboratories Inc. | For profit | MKTG | Aug 31, 1992 |
| Genus Oncology, LLC | For profit | MKTG | Feb 24, 2014 |
| Genus Oncology, LLC | For profit | NDA2 | Feb 24, 2014 |
| Glenmark Pharmaceuticals | For profit | MKTG | Dec 22, 2010 |
| Glenmark Pharmaceuticals | For profit | SYN | Jun 22, 2017 |
| Halsey | For profit | MKTG | — |
| Heritage Pharma | For profit | NDA2 | May 18, 1984 |
| Heritage Pharma | For profit | MKTG | Feb 12, 1986 |
| Heritage Pharma | For profit | SYN | May 18, 1984 |
| Heritage Pharma | For profit | SYN | May 18, 1984 |
| Hetero Labs Ltd | For profit | MKTG | Apr 12, 2011 |
| Hikma | For profit | SYN | Mar 18, 1987 |
| Hikma | For profit | MKTG | Mar 18, 1987 |
| Hospira | For profit | MKTG | Apr 19, 2016 |
| Hospira | For profit | SYN | Apr 19, 2016 |
| Inwood Laboratories | For profit | MKTG | Mar 15, 1989 |
| Jubilant Innovation Ltd. | For profit | MKTG | Oct 5, 2015 |
| Merck | For profit | NDA | Jun 10, 1965 |
| Mutual Pharmaceutical | For profit | MKTG | Oct 3, 1986 |
| Mylan | For profit | NDA2 | Apr 20, 1984 |
| Mylan | For profit | SYN | Mar 20, 2014 |
| Navinta | For profit | MKTG | Jul 19, 2017 |
| Novartis | For profit | MKTG | May 28, 1998 |
| Novast Labs | For profit | MKTG | May 8, 2017 |
| Novitium Pharma | For profit | MKTG | Jan 12, 2024 |
| Parke-Davis | For profit | NDA2 | — |
| Pfizer | For profit | MKTG | Apr 19, 2016 |
| Pliva | For profit | MKTG | Mar 18, 1987 |
| Recordati | For profit | NDA2 | Jan 30, 1985 |
| Rising Pharmaceuticals | For profit | MKTG | Apr 20, 1984 |
| Rising Pharmaceuticals | For profit | SYN | Mar 20, 2014 |
| Rising Pharmaceuticals | For profit | NDA2 | Apr 20, 1984 |
| Sandoz | For profit | MKTG | Apr 29, 1987 |
| Sun Pharmaceuticals | For profit | MKTG | Mar 28, 2013 |
| Sun Pharmaceuticals | For profit | SYN | Feb 9, 1987 |
| Superpharm | For profit | MKTG | Oct 10, 1986 |
| Teva | For profit | NDA2 | May 4, 1984 |
| Teva | For profit | SYN | Nov 7, 1985 |
| Teva | For profit | MKTG | Nov 7, 1985 |
| Watson Pharmaceuticals | For profit | MKTG | May 18, 1987 |
| Watson Pharmaceuticals | For profit | SYN | Dec 9, 2013 |
| Watson Pharmaceuticals | For profit | NDA2 | — |
| West-Ward Pharmaceutical | For profit | MKTG | Jul 16, 2008 |
| Zydus Discovery DMCC | For profit | MKTG | Sep 25, 2017 |
| Zydus Discovery DMCC | For profit | SYN | Nov 15, 2010 |
| Zydus Discovery DMCC | For profit | SYN | Aug 2, 2023 |
| Zydus Discovery DMCC | For profit | SYN | Nov 15, 2010 |
| Zyla Life Sciences | For profit | NDA2 | Jun 10, 1965 |
| Zyla Life Sciences | For profit | MKTG | Oct 10, 1985 |
| Zyla Life Sciences | For profit | SYN | Aug 13, 1984 |